Inmazeb (REGN-EB3) and Ebanga (Ansuvimab) monoclonal antibodies for Ebola treatment (youtube.com)

• Inmazeb (REGN-EB3) is a combination of three monoclonal antibodies.
• Ebanga (Ansuvimab) is a single monoclonal antibody.
• Both are FDA-approved for Ebola Zaire and reduce mortality.

"This article explains the approved monoclonal antibody therapies Inmazeb and Ebanga for Ebola. Inmazeb is a combination of three antibodies, Ebanga a single antibody. Both are FDA-approved for Zaire ebolavirus and have significantly reduced case fatality rates in clinical trials."